Transforming protein RhoA (RhoA) (RhoA)

Transforming protein RhoA (RhoA) is a small GTPase of the Ras superfamily that serves as a pivotal regulator of the actin cytoskeleton and various cellular processes including migration, adhesion, and cell cycle progression (UniProt: P61586). It operates as a molecular switch, alternating between an inactive GDP-bound form and an active GTP-bound form that interacts with downstream effectors like Rho-associated protein kinase (ROCK) (PubMed: 16517864). RhoA signaling is frequently dysregulated in various pathologies; for instance, its overexpression or hyperactivation is linked to tumor metastasis and invasion in cancers such as gastric and breast carcinoma (PubMed: 25639197). In cardiovascular medicine, the RhoA/ROCK pathway is a target for treating hypertension and vasospasm, while in ophthalmology, ROCK inhibitors are used to lower intraocular pressure in glaucoma (StatPearls: NBK554544). Pharmacological targeting of this pathway includes direct RhoA inhibitors, inhibitors of geranylgeranylation, and most successfully, inhibitors of the downstream kinase ROCK (PubMed: 29153511). Additionally, RhoA mutations, such as the G17V variant, have been identified as drivers in specific hematologic malignancies like angioimmunoblastic T-cell lymphoma (PubMed: 24413737). Therapeutic challenges include the ubiquitous nature of RhoA, which can lead to systemic side effects like hypotension when the pathway is inhibited globally. Despite these challenges, the pathway remains a high-interest area for drug development in fibrosis and neuroregeneration.

Other names

Ras homolog family member AARHAARH12RHO12Rho cDNA clone 12

RhoA functions as a molecular switch that cycles between an inactive GDP-bound state and an active GTP-bound state. Therapeutic strategies involve inhibiting downstream effectors like ROCK, blocking post-translational geranylgeranylation required for membrane localization (e.g., via statins), or directly interfering with GTP binding and exchange (PubMed: 29153511).